ClinicalTrials.gov listed phase 3 primary completion for lurbinectedin on 2026-04-10 in the LAGOON study, a randomized trial in relapsed small-cell lung cancer. The record shows the study is completed and enrolled 705 participants.
Background
The trial studied relapsed small-cell lung cancer, a setting in which participants had failed one prior platinum-containing line. The record identifies lurbinectedin as the experimental drug and compares it with investigator’s choice control treatment.
Trial design
LAGOON was a multicenter, open-label, randomized, controlled phase III study. It tested two experimental arms: lurbinectedin as single agent and lurbinectedin plus irinotecan, against investigator’s choice of topotecan or irinotecan in the control arm.
What this means
Primary completion means the trial reached the point at which its main outcome assessment was expected, but the ClinicalTrials.gov record provided here does not include posted outcome results. For clinicians and researchers, the completed status and large enrollment suggest the study may be important for understanding where lurbinectedin fits among post-platinum options for relapsed small-cell lung cancer.
Source
This information is based on ClinicalTrials.gov trial record NCT05153239, updated for primary completion on 2026-04-10. The record is available at clinicaltrials.gov.